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Abstract
Complex circuitry and limited regenerative power make 
central nervous system (CNS) disorders the most chal-
lenging and difficult for functional repair. With elusive 
disease mechanisms, traditional surgical and medical 
interventions merely slow down the progression of the 
neurodegenerative diseases. However, the number of 
neurons still diminishes in many patients. Recently, 
stem cell therapy has been proposed as a viable op-
tion. Mesenchymal stem cells (MSCs), a widely-studied 
human adult stem cell population, have been discov-
ered for more than 20 years. MSCs have been found all 
over the body and can be conveniently obtained from 
different accessible tissues: bone marrow, blood, and 
adipose and dental tissue. MSCs have high proliferative 
and differentiation abilities, providing an inexhaustible 
source of neurons and glia for cell replacement thera-
py. Moreover, MSCs also show neuroprotective effects 
without any genetic modification or reprogramming. In 
addition, the extraordinary immunomodulatory prop-
erties of MSCs enable autologous and heterologous 
transplantation. These qualities heighten the clinical ap-
plicability of MSCs when dealing with the pathologies of 
CNS disorders. Here, we summarize the latest progress 
of MSC experimental research as well as human clinical 
trials for neural and retinal diseases. This review article 
will focus on multiple sclerosis, spinal cord injury, au-
tism, glaucoma, retinitis pigmentosa and age-related 
macular degeneration.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Central nervous system (CNS) disorders are 
the most challenging and difficult for functional repair. 
Neurons are still diminishing in many patients despite 
surgical and medical interventions. Stem cell therapy 
has been proposed as a viable option. Mesenchymal 
stem cell (MSC) is a widely-studied human adult stem 
cell population. MSCs can be conveniently obtained 
from different accessible tissues. MSCs have high pro-
liferative and differentiation abilities, providing an inex-
haustible source of neurons and glia. MSCs also show 
neuroprotective effects and possess extraordinary im-
munomodulatory properties. These qualities heighten 
the clinical applicability of MSCs when dealing with the 
pathologies of CNS disorders.
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TOPIC HIGHLIGHT
STEM CELL THERAPY AND 
MESENCHYMAL STEM CELLS
Stem cells are undifferentiated cells defined by their abil-
ity to self-renew and differentiate into mature cells. Stem 
cells are attractive because they are highly proliferative, 
implying that an inexhaustible number of  mature cells 
can be generated from a given stem cell source. On this 
basis, cell replacement therapy has been proposed in re-
cent years as a viable alternative for various pathologies. 
Cell replacement therapy hypothesizes that new retinal 
cells could be generated from stem cells so as to substi-
tute the damaged cells in the diseased retina. This theory 
is mainly established from embryonic stem cells (ESCs) 
and induced pluripotent stem cells (iPSCs). In addition to 
cell replacement function, stem cells could have another 
protective effect, the paracrine effect. The paracrine ef-
fects of  stem cells are believed to modulate the micro-
environment of  the diseased tissues so as to protect the 
injured cells, promote survival and activate any available 
endogenous repair mechanisms. This latter observation 
applies mainly to the transplantation of  adult stem cells.
Adult stem cells are defined as the stem cells found in 
fully developed tissues. The function of  adult stem cells 
is the maintenance of  adult tissue specificity by homeo-
static cell replacement and tissue regeneration[1]. Adult 
stem cells are presumed quiescent within adult tissues, 
but divide infrequently to maintain their own niche by 
generating a stem cell clone and a transiently-amplifying 
cell. The transiently-amplifying cells will undergo a lim-
ited number of  cell divisions before terminal differentia-
tion into mature functional tissue cells. The existence of  
adult stem cells has been reported in multiple organs; 
these include: brain, heart, skin, intestine, testis, muscle 
and blood, among others.
Mesenchymal stem cells (MSCs), also called marrow 
stromal cells, are an adult stem cell population of  stro-
mal progenitor cells of  mesodermal origin[2]. MSCs were 
originally identified in the bone marrow, representing 
0.001%-0.01% of  the bone marrow population. MSCs 
can also be found in other systems all over the body, such 
as adipose tissue, liver, umbilical cord, central nervous 
system (CNS) and dental tissues[3]. According to the In-
ternational Society of  Cellular Therapy[4], the minimal 
criteria to define MSCs are: (1) grown in adherence to 
plastic surface of  dishes when maintained in standard 
culture conditions; (2) positive expression of  cytospe-
cific cell surface markers (CD105, CD90 and CD73) and 
negative expression of  other cell surface markers (CD45, 
CD34, CD14 and CD11b); and (3) capacity to differenti-
ate into mesenchymal lineages, under appropriate in vitro 
conditions. In addition to the expression of  the three 
cell surface markers, MSCs also express CD29, CD44, 
CD146 and STRO-1[5].
The function of  MSCs is to differentiate into osteo-
cytes, chondrocytes, myoblasts and adipocytes[6,7]. An 
increasing number of  studies, however, report that MSCs 
are capable of  giving rise to cells of  an entirely distinct 
lineage, including neuron-like cells. MSCs are not only 
able to differentiate into neurons for cell replacement 
therapy, they also exert paracrine effects by modulating 
the plasticity of  damaged host tissues, secreting neuro-
trophic and survival-promoting growth factors, restor-
ing synaptic transmitter release, integrating into existing 
neural and synaptic networks, and re-establishing func-
tional afferent and efferent connections[8]. These para-
crine activities have not been reported in ESCs or iPSCs. 
Moreover, MSCs possess strong immunosuppressive 
properties and inhibit the release of  pro-inflammatory 
cytokines[9]. This allows autologous, as well as, allogeneic 
transplantation of  MSCs without the need of  pharma-
cological immunosuppression. Furthermore, MSCs can 
be transplanted directly without genetic modification or 
pre-treatments, and are able to migrate to the tissue in-
jury sites[10]. In addition, there is no teratoma formation 
concern after transplantation[11], and no moral objection 
or ethical controversies involved in their attainment[12]. 
These advantageous properties, as well as the expansion 
potential of  MSCs initiate the idea of  clinical applications 
of  MSCs to treat different human diseases, especially 
CNS disorders. Currently, over 100 MSC clinical trials for 
different diseases have been listed by the United States 
National Institutes of  Health trial database (www.clini-
caltrials.gov), indicating that MSC therapy is a popular 
trend for the field of  regenerative medicine in the years 
to come.
This review article provides an update on the progress 
of  MSC experimental research as well as human clinical 
trials for neural and retinal diseases with emphasis on 
multiple sclerosis, spinal cord injury, autism, glaucoma, 
retinitis pigmentosa and age-related macular degenera-
tion.
MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is an immune-mediated neurode-
generative disorder of  the CNS, affecting over 1.3 million 
people worldwide. The histopathological hallmark of  
MS is the formation of  an inflammatory plaque, which 
originates from a breach in the integrity of  the blood-
brain barrier[13]. The histologic features of  lesions in MS 
include: lymphocyte infiltration, loss of  oligodendro-
cytes, demyelination, and widespread axonal damage[14]. 
Myelin-reactive T cells, which secrete interferon- and 
interleukins, have been suggested to be responsible for 
the inflammatory demyelination seen in MS[15]. Currently, 
there are three treatment options approved by the Food 
and Drug Administration (FDA) for MS: administration 
of  interferon beta, glatiramer acetate, or mitoxantrone[16]. 
However, there is still no medical cure for MS.
Experimental autoimmune encephalomyelitis (EAE), 
the best known and most commonly used model for MS, 
mechanistically defines the immune processes responsible 
for the clinical manifestations and development of  MS[17]. 
This animal model provides insight for the application 
of  immunotherapy to treat MS[18]. MSCs have been pro-
Ng TK et al . MSC therapy progress in CNS diseases
112 April 26, 2014|Volume 6|Issue 2|WJSC|www.wjgnet.com
posed as a treatment for autoimmune diseases, includ-
ing MS, because of  their immunosuppressive properties 
and neural repair function[19]. Transplantation of  human 
MSCs into animals with ongoing EAE results in rapid 
and sustained functional recovery due to a reduced num-
ber of  inflammatory myelin-specific Th1 cells and astro-
cytes as well as an increased number of  inflammatory-
inhibiting Th2 cells, oligodendrocytes and neurons[20]. 
This functional benefit is a critical stepping-stone towards 
effective MSC therapies in MS patients.
Among all of  the CNS disorders, MS has the high-
est number of  registered clinical trials. Altogether there 
are 14 registered clinical trials for MS (Table 1), and two 
of  them have been published. The study from Israel is a 
phase-1/2 open safety clinical trial to evaluate the feasi-
bility, safety and immunological effects of  intrathecal and 
intravenous administration of  autologous MSCs in 15 MS 
patients (NCT00781872; http://clinicaltrials.gov/)[21]. No 
major adverse effects have been reported in this study, 
and the mean Expanded Disability Status Scale (EDSS) 
improved from 6.7 to 5.9 (EDSS steps 1.0 to 4.5: MS 
patients are fully ambulatory, whereas EDSS steps 5.0 to 
9.5: MS patients are impaired to ambulation). Moreover, 
magnetic resonance imaging visualized the MSCs in the 
occipital horns of  the ventricles, indicating migration of  
the cells. In addition, the proportion of  CD4+/CD25+ 
regulatory T cells increased, whereas the proliferative 
responses of  lymphocytes decreased. The mesenchymal 
stem cells in the multiple sclerosis trial (MSCIMS) origi-
nated in the United Kingdom, is an open-label phase 2a 
proof-of-concept study of  autologous MSCs in second-
ary progressive MS (NCT00395200; http://clinicaltrials.
gov/)[22,23]. In this study, 10 patients received intravenous 
infusion of  autologous bone marrow-derived MSCs (1.6 
× 106 cells per kg body weight). The “sentinel lesion ap-
proach” assessing the anterior visual pathway was used 
to measure the efficacy of  treatment. Results show that 
treatment improved visual acuity, visual evoked response 
latency, and increased the optic nerve area of  the recipi-
ents. No serious adverse events were identified. For other 
clinical trials, mainly autologous MSCs have been used, 
although one study from China uses umbilical cord MSCs 
(NCT01364246; http://clinicaltrials.gov/). Interestingly, 
an open-label phase I clinical trial from New York was 
designed to evaluate autologous MSC-derived neural pro-
genitor cells in progressive MS patients (NCT01933802; 
http://clinicaltrials.gov/) even though neural stem cells 
from EAE animals mainly develop astrocytes rather than 
oligodendrocytes, or oligodendrocyte precursor cells and 
neurons[20].
SPINAL CORD INJURY
Spinal cord injury (SCI) is the most devastating and trau-
matic disorder among CNS conditions[24]. The worldwide 
frequency of  SCI is about 40 cases per million individu-
als[25]. SCI can be caused by traffic accidents, violent as-
saults, falls, sport and other traumatic events. Depending 
on the injury location, extent, phases and time frames, 
SCI therapeutic strategies can vary greatly[26]. Most SCI 
patients are in the chronic phase, characterized by ongo-
ing demyelination, local inflammation and apoptosis, de-
creased number of  activated macrophages, and formation 
of  glial scar and pseudocysts[27]. The present standard 
treatment for SCI patients is surgical intervention, high 
doses of  methylprednisolone, and symptomatic therapy 
followed by rehabilitation[28]. New neuroregenerative 
strategies will be focused on neuroprotection and axonal 
regeneration in a permissive environment.
Cellular therapy aims to reconstruct the spinal cord 
through cellular replacement, glial scar remodeling, axo-
nal guidance, and filling of  formed syringomyelia[29]. In 
vivo administration of  MSCs in different SCI animal mod-
els showed functional recovery including: increased mo-
tor activity and sensation in the paralyzed limbs, reduced 
cavity formation in the spinal cord, and axonal sprouting 
through the glial scar[30,31]. The objective of  MSC applica-
tion is to ameliorate the consequences of  secondary in-
jury by preserving the host nerve cells, rather than replac-
ing them[32].
Comparable to MS studies, there are 11 registered 
clinical trials using MSCs for SCI treatment (Table 1), 
among which two studies (one from Egypt and one from 
South Korea) have been completed. The Korean study 
investigated the safety of  single intravenous infusion of  
autologous adipose tissue-derived MSCs (4 × 108 cells) in 
8 male patients with chronic SCI (NCT01274975; http://
clinicaltrials.gov/)[33]. No adverse events were observed. 
Although one patient showed improvement in the Amer-
ican Spinal Injury Association (ASIA) scale from grade 
A (No sensory or motor function is preserved in sacral 
segments S4-S5) to grade C (Motor function is preserved 
below the neurologic level, and most key muscles below 
the neurologic level have muscle grade less than 3) and 
three patients showed motor score improvement, this 
phase I clinical trial might not have the statistical power 
to conclude on the efficacy of  treatment effect with adi-
pose tissue-derived MSCs on SCI. The study conducted 
in Egypt (NCT00816803; http://clinicaltrials.gov/), is 
a Phase-1/2 clinical trial applying bone marrow-derived 
MSCs at the injury site of  chromic SCI patients. How-
ever, no results of  this study have been released. Finally, 
there are two Phase-3 clinical trials taking place in China 
(NCT01873547; http://clinicaltrials.gov/) and Korea 
(NCT01676441; http://clinicaltrials.gov/). The study 
in China plans to use umbilical cord MSCs to treat 100 
chronic SCI patients compared to the rehabilitation-only 
group and no stem cell and rehabilitation group, whereas 
the study in Korea was designed to transplant bone mar-
row-derived MSCs to treat 32 chronic SCI patients. For 
other ongoing clinical trials in SCI, the approaches are 
mainly intrathecal transplantation of  bone marrow-de-
rived MSCs and adipose tissue-derived MSCs in chronic 
SCI patients.
AUTISM
Autism belongs to a spectrum of  heterogeneous neuro-
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Table 1  Registered clinical trials on mesenchymal stem cells for neural diseases
Identifier Country Status Study Phase of 
trial
Estimated number 
of patients
Estimated 
trial end
Disease
NCT01377870 Iran Recruiting Evaluation of autologous mesenchymal stem cell 
transplantation (effects and side effects) in multiple 
sclerosis
Phase 1/2   30 2013 Multiple 
sclerosis
NCT01895439 Jordan Recruiting Safety and efficacy study of autologous bone marrow 
mesenchymal stem cells in multiple sclerosis
Phase 1/2   30 2014 Multiple 
sclerosis
NCT01883661 India Not yet 
recruiting
Safety and efficacy of  MSCs in MS Phase 1/2   15 2015 Multiple 
sclerosis
NCT00395200 United 
Kingdom
Completed MSCIMS Phase 1/2   10 2010 Multiple 
sclerosis
NCT01854957 Italy Recruiting MESEMS Phase 1/2   20 2014 Multiple 
sclerosis
NCT01730547 Sweden Recruiting Mesenchymal stem cells for multiple sclerosis Phase 1/2   15 2015 Multiple 
sclerosis
NCT01364246 China Recruiting Safety and efficacy of umbilical cord 
mesenchymal stem cell therapy for patients 
with progressive multiple sclerosis and neuromyelitis 
optica
Phase 1/2   20 2014 Multiple 
sclerosis
NCT01056471 Spain Unknown Autologous mesenchymal stem cells from adipose 
tissue in patients with secondary progressive multiple 
sclerosis (CMM/EM/2008)
Phase 1/2   30 2012 Multiple 
sclerosis
NCT01228266 Spain Active, not 
recruiting
Mesenchymal stem cell transplantation in MS (CMM-
EM)
Phase 2   16 2013 Multiple 
sclerosis
NCT00813969 United 
States
Active, not 
recruiting
Autologous MSC transplantation in MS Phase 1   24 2014 Multiple 
sclerosis
NCT01933802 United 
States
Not yet 
recruiting
Intrathecal administration of autologous  MSC-NP in 
patients with multiple sclerosis
Phase 1   20 2016 Multiple 
sclerosis
NCT01606215 United 
Kingdom
Recruiting STREAMS Phase 1/2   13 2015 Multiple 
sclerosis
NCT01745783 Spain Recruiting Mesenchymal cells from autologous bone marrow, 
administered intravenously in patients diagnosed with 
multiple sclerosis
Phase 1/2   30 2014 Multiple 
sclerosis
NCT00781872 Israel Unknown MSCs for the treatment of MS Phase 1/2   20 2009 Multiple 
sclerosis
NCT01694927 Chile Enrolling by 
invitation
Autologous mesenchymal stem cells in spinal cord 
injury (SCI) patients (MSC-SCI)
Phase 2   30 2014 Spinal cord 
injury
NCT01446640 China Recruiting Mesenchymal stem cells transplantation to patients 
with spinal cord injury (MSC)
Phase 1/2   20 2014 Spinal cord 
injury
NCT01676441 South 
Korea
Recruiting Safety and efficacy of autologous mesenchymal stem 
cells in chronic spinal cord injury
Phase 2/3   32 2014 Spinal cord 
injury
NCT01769872 South 
Korea
Recruiting Safety and effect of adipose tissue derived 
mesenchymal stem cell implantation in patients with 
spinal cord injury
Phase 1/2   15 2014 Spinal cord 
injury
NCT01162915 United 
States
Active, not 
recruiting
Transfer of bone marrow derived stem cells for the 
treatment of spinal cord injury
Phase 1   10 2013 Spinal cord 
injury
NCT01274975 South 
Korea
Completed Autologous adipose derived mscs transplantation in 
patient with spinal cord injury
Phase 1     8 2010 Spinal cord 
injury
NCT01624779 South 
Korea
Recruiting Intrathecal transplantation of autologous 
adipose tissue derived msc in the patients with spinal 
cord injury
Phase 1   15 2013 Spinal cord 
injury
NCT01393977 China Unknown Difference between rehabilitation therapy and stem 
cells transplantation in patients with spinal cord injury 
in China
Phase 2   60 2012 Spinal cord 
injury
NCT01873547 China Recruiting Different efficacy between rehabilitation therapy and 
stem cells transplantation in patients with SCI in China 
(SCI-Ⅲ)
Phase 3 300 2014 Spinal cord 
injury
NCT01325103 Brazil Unknown Autologous bone marrow stem cell transplantation in 
patients with spinal cord injury
Phase 1   20 2013 Spinal cord 
injury
NCT00816803 Egypt Completed Cell transplant in spinal cord injury patients Phase 1/2   80 2008 Spinal cord 
injury
NCT01343511 China Completed Safety and efficacy of stem cell therapy in patients with 
autism
Phase 1/2   37 2011 Autism
Information obtained from http://clinicaltrials.gov/. MSCs: Mesenchymal stem cells; MS: Multiple sclerosis; MSCIMS: Mesenchymal Stem Cells in 
Multiple Sclerosis; MESEMS: MEsenchymal StEm Cells for Multiple Sclerosis; MSC-NP: Mesenchymal Stem Cell-derived Neural Progenitors; STREAMS: 
Stem Cells in Rapidly Evolving Active Multiple Sclerosis.
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developmental disorders[34]. It is characterized by abnor-
malities in social interaction, impaired verbal and nonver-
bal communication, and repetitive, obsessive behavior[35]. 
According to the Centers for Disease Control, the preva-
lence of  autism hovers around 60 in every 10000 chil-
dren[36]. Even though there is no defined gold standard 
approach, current interventions for autism can be divided 
into behavioral, nutritional and pharmacological[37]. Medi-
cal interventions aim to ameliorate the neuropsychiatric 
disorders associated with autism. The medications include 
selective serotonin reuptake inhibitors (SSRI’s), typical 
and atypical anti-psychotic drugs, psycho-stimulants, α-2 
agonists, β blockers, lithium, anti-convulsant mood stabi-
lizers and anti-depressants[38-40]. Unfortunately, autism is 
still not treatable.
The pathogenic mechanism of  autism is not clearly 
understood and remains elusive. Nevertheless, two 
pathologies are commonly found within the autism pa-
tients: the first observation is an impaired central ner-
vous system circulation and hypoperfusion to the brain, 
whereas the second observation is systemic T cell and 
B cell abnormalities as well as active neuroinflammatory 
processes in the brain[41]. Based on the immunomodula-
tory properties of  MSCs, therapies employing MSCs 
have been proposed to target the immune deregulation 
observed in autism. Basically, it is believed that MSCs are 
able to inhibit the release of  pro-inflammatory cytokines 
and have strong immunosuppressive activity[42]. This not 
only allows for autologous transplantation, but also het-
erologous transplantation without the requirement of  
pharmacological immunosuppression[43].
Currently, there is only one registered human clinical 
trial using MSCs to treat autism (NCT01343511; http://
www.clinicaltrials.gov/; Table 1). This study aimed to test 
the safety and efficacy of  human umbilical cord MSCs 
and human cord blood mononuclear cell transplantation 
in Chinese patients with autism[44]. Outcomes from this 
study assuaged the safety concerns in using MSCs and 
mononuclear cells for transplantation in autism patients, 
and no severe adverse effects were observed. In addi-
tion, results also showed that combined transplantation 
of  MSCs and mononuclear cells (combination group) 
had better therapeutic effects than transplantation of  
mononuclear cells alone (CBMNC group) in terms of  
the Childhood Autism Rating Scale (CARS) total score 
(combination group: 28.00 ± 6.18; CBMNC group: 37.14 
± 10.15; CARS total score > 30 means the child is con-
sidered to be autistic), Clinical Global Impression (CGI) 
scale (combination group: 88% much improved or high-
er; CBMNC group: 49% much improved or higher) and 
the Aberrant Behavior Checklist (ABC) total score (com-
bination group: 36.78 ± 16.95; CBMNC group: 58.36 ± 
31.73; a high score indicates greater severity while a low 
score indicates a milder degree of  difficulty).
GLAUCOMA
Glaucoma is a group of  chronic, degenerative optic 
neuropathies. It is characterized by a slow progressive 
degeneration of  retinal ganglion cells (RGCs) and their 
axons, which results in visual field defects[45]. Glaucoma 
is the leading cause of  irreversible blindness, affecting 
more than 60 million people worldwide[46]. Traditional 
and current treatments for glaucoma are based on surgi-
cal or medical interventions to slow disease progression 
and limit visual loss[47]. However, in many patients, the 
numbers of  RGCs still diminish, and glaucoma cannot be 
completely cured.
The molecular basis of  glaucoma is complex. The 
pathophysiological mechanisms leading to RGC degener-
ation in glaucoma include a complex interaction between 
primary axonal injury, neurotrophic factor deprivation, 
ischemia, oxidative stress, mitochondrial dysfunction 
and inflammation[48]. New therapies aim to supplement 
neurotrophic factors, such as brain-derived neurotrophic 
factor (BDNF), ciliary neurotrophic factor (CNTF), glial 
cell line-derived neurotrophic factor (GDNF) and nerve 
growth factor (NGF)[49]. However, repeated injections are 
needed to achieve an observable effect[50]. To avoid mul-
tiple injections, cell-based delivery of  neurotrophic fac-
tors was proposed. A phase-I clinical trial for glaucoma 
(NCT01408472; http://clinicaltrials.gov/) using geneti-
cally modified CNTF-secreting retinal pigment epithelial 
cells (NT-501 CNTF implant) has already been launched-
the outcomes have not been reported yet. Since MSCs 
can produce neurotrophic factors, including BDNF, 
CNTF, GDNF and basic fibroblast growth factor (bFGF), 
without the requirement of  genetic modification, MSC 
transplantation has been suggested as a potential reser-
voir for neurotrophic factor secretion[51]. Bone marrow-
derived MSC transplantation increases RGC survival in a 
model of  transient ischemia followed by reperfusion[52], 
and reduces RGC loss in ocular hypertension models[53,54]. 
Similarly, transplantation of  human umbilical cord blood 
MSCs promotes RGC survival in an optic nerve crush 
model even after 7 d of  injury[55]. In addition, intracranial 
human umbilical cord blood MSC transplantation at the 
site of  optic tract transaction also protects RGCs and in-
duces axonal regeneration[56]. The neuroprotective effect 
of  MSCs on RGC survival has clearly been proven, and 
the first clinical trial using bone marrow-derived MSCs 
on glaucoma in Florida (Stem Cell Ophthalmology Treat-
ment Study (SCOTS)) has just started in August 2013 
(NCT01920867; http://clinicaltrials.gov/; Table 2). This 
study will be complete in 2017.
RETINITIS PIGMENTOSA AND AGE-
RELATED MACULAR DEGENERATION
Retinitis pigmentosa (RP) is characterized by a clas-
sic pattern of  difficulties in dark adaptation and night 
blindness in adolescence, loss of  mid-peripheral visual 
field in young adulthood and central vision later in life. 
These are due to the severe attenuation of  rod and cone 
photoreceptors[57]. RP is one of  the hereditary degenera-
tive diseases, affecting 1 in 4000 individuals. Age-related 
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macular degeneration (AMD) is the leading cause of  ir-
reversible blindness in people aged 50 years or above in 
the developed world[58]. It influences the central portion 
of  the retina (the macula). Early AMD is characterized by 
drusen (pale yellowish lesions), or by hyperpigmentation 
and hypopigmentation of  retinal pigment epithelium in 
the macula. Late AMD is divided into the “non-exudative” 
and “exudative” forms. The non-exudative form (geo-
graphic atrophy) starts with a sharply demarcated round 
or oval hypopigmented spot in which large choroidal ves-
sels are visible, whereas the exudative form, characterized 
by choroidal neovascularization, is the detachment of  the 
neuroretina or RPE from Bruch’s membrane by serous 
or hemorrhagic fluid[59,60].
Both RP and AMD involve photoreceptor cell death. 
MSC research studies targeting this common pathology 
can be divided into two categories: first, cell replacement-
based studies aim to generate photoreceptor cells from 
different sources of  MSCs. MSCs from the trabecular 
meshwork as well as the conjunctiva have been used to 
produce photoreceptor-like cells in vitro[61,62]. Interestingly, 
subretinal injection of  MSCs has also been reported to 
induce differentiation into photoreceptor cells in a so-
dium iodate-induced retinal degeneration rat model[63]. 
Second, studies based on paracrine effects hypothesize 
that MSCs can secrete neurotrophic factors to protect 
against photoreceptor degeneration in different animal 
models. Transplantation of  bone marrow-derived MSCs 
can rescue photoreceptor cells of  the dystrophic retina 
in the rhodopsin knockout mouse model[64]. Moreover, 
intravenous injection of  bone marrow-derived MSCs res-
cue photoreceptor cells as well as visual function in the 
Royal College of  Surgeons rat model[65]. For AMD, beside 
photoreceptor cell loss, retinal pigment epithelial (RPE) 
cells are also affected. Adipose tissue-derived MSCs can 
be induced to an RPE phenotype[66]. In addition, adipose 
tissue-derived MSCs rescue mitomycin C-treated RPE 
cell lines (ARPE19) from death in culture[67]. Further-
more, subretinal injected MSCs adopt RPE morphology 
and preserve the retinal layer integrity in the sodium 
iodate-induced retinal degeneration rat model[68].
To date, there are three ongoing registered clinical 
trials using MSCs on RP (Table 2). The first clinical trial 
aims to determine the feasibility and safety of  human 
adult bone marrow-derived MSCs by intravitreal injection 
in patients with RP in Thailand (NCT01531348; http://
clinicaltrials.gov/). The second clinical trial is the Stem 
Cell Ophthalmology Treatment Study (SCOTS) in Flori-
da (NCT01920867; http://clinicaltrials.gov/) proposed to 
use autologous bone marrow-derived MSCs by different 
means of  injection (retrobulbar, subtenon, intravitreal, 
intraocular, subretinal and intravenous). The third clinical 
trial is a Phase-1/2 open labeled study done in India to 
evaluate the safety and efficacy of  bone marrow-derived 
MSCs in RP (NCT01914913; http://clinicaltrials.gov/). 
For AMD, there is only one registered clinical trial us-
ing bone marrow-derived MSCs (Table 2), the Stem Cell 
Ophthalmology Treatment Study (SCOTS) in Florida 
(NCT01920867; http://clinicaltrials.gov/). Results from 
these studies have not been reported yet.
CONCLUSION
MSCs have been discovered for more than 20 years[69], 
and have been found all over the body. MSCs can be con-
veniently obtained from different accessible tissues: bone 
marrow, blood, and adipose and dental tissue. They can 
also be easily expanded in standard culture conditions. In 
addition to the above mentioned characteristics, MSCs 
demonstrate neuroprotective effects, immunomodulatory 
properties and self-migratory activity, making them an 
attractive therapeutic tool. In recent years, MSC research 
has already begun the transition from preclinical experi-
ments to human clinical trials. There are currently more 
than 60 MSC clinical trials dealing with CNS disorders 
and three clinical trials on retinal diseases. Although 
transient rash, self-limiting bacterial infections or fever 
might occur in some patients after MSC transplantation, 
serious adverse events have never been observed. This 
can foresee that MSC transplantation will become routine 
clinical practice for disease treatment in the near future. 
However, there are critical challenges still needed to be 
conquered before MSC therapy can be adopted in daily 
clinical practice. These include: (1) poor MSC retention 
in vivo; (2) poor MSC engraftment, viability and function 
in vivo; (3) unclear mechanisms of  action; and (4) lack 
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Table 2  Registered clinical trials on mesenchymal stem cells for retinal diseases
Identifier Country Status Study Phase of 
trial
Estimated number of 
patients
Estimated trial 
end
Disease
NCT01531348 Thailand Enrolling by 
invitation
Feasibility and safety of adult human 
bone marrow-derived mesenchymal 
stem cells by intravitreal injection in 
patients with retinitis pigmentosa
Phase 1   10 2014 Retinitis pigmentosa
NCT01914913 India Not yet 
recruiting
Clinical study to evaluate safety and 
efficacy of stem cell therapy in retinitis 
pigmentosa
Phase 
1/2
  15 2015 Retinitis pigmentosa
NCT01920867 United 
States
Recruiting Stem cell ophthalmology treatment 
study
300 2017 Glaucoma, retinitis 
pigmentosa, age-related 
macular degeneration
Information obtained from http://clinicaltrials.gov/.
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of  standardized trials[70]. Moreover, few studies showed 
the contradictory results of  MSC immunomodulatory 
properties. This might be explained by the heterogeneous 
MSC population. TLR4-primed human MSCs (MSC1) 
mostly secrete pro-inflammatory cytokines (IL-6, IL-8) 
while TLR3-primed human MSCs (MSC2) express most-
ly immunosuppressive mediators (IL-10, IDO, TSG-6)[71]. 
Addition of  fewer MSCs (10-1000) would led to a less 
consistent suppression or a marked lymphocyte prolifera-
tion in culture, whereas addition of  10000-40000 MSCs 
have an inhibitory effect[72]. Besides, there are uncertain-
ties that must be answered. What is the optimal cell num-
ber for transplantation? Which MSC types are optimal 
for regenerative medicine? When is the optimal stage to 
receive MSC therapy? Which transplantation route is suit-
able for each individual CNS disorder? Further research 
is needed to understand the mechanisms elicited by stem 
cells in regenerating damaged tissues after transplanta-
tion.
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